FDA approves AstraZeneca's Imfinzi with enfortumab vedotin for bladder cancerNov 16Regulatory decisionAstraZenecadurvalumab
FDA approves durvalumab plus enfortumab vedotin for muscle invasive bladder cancerNov 13Regulatory decisionAstraZenecadurvalumabUpdated
Bicara reaches substantial enrollment in HPV-negative head and neck cancer trialNov 9Quarterly updateArriVent BioPharma, Inc.Bicara Therapeutics
FDA approves durvalumab plus BCG for high-risk non-muscle invasive bladder cancerNov 6Regulatory decisionAstraZenecadurvalumab
Merck collaborator posts pancreatic cancer results; new MK-1045, COPD trial records surfaceNov 6Weekly roundup, 14 itemsDaiichi SankyoensifentrineUpdated
AstraZeneca completes AZD4144-itraconazole PK study; posts five trial records this weekNov 6Weekly roundup, 12 itemsanifrolumab-fniaAstraZenecaUpdated
Emergent BioSolutions cuts 2026 revenue and EBITDA guidance as Q3 sales fall 52%Nov 2Quarterly updateAmgenAprea Therapeutics
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacyOct 30Weekly roundup, 8 itemsalbuterol sulfate and budesonideAstraZenecaUpdated
Imunon agrees to sell ThermoDox rights to VoxelDox TherapeuticsOct 21Clinical readoutEikon TherapeuticsGenmab A/S
Fred Hutchinson posts Phase II acalabrutinib results; AstraZeneca's AZD0780 LDL-C trial completesOct 16Weekly roundup, 11 itemsacalabrutinibAstraZenecaUpdated
TerSera recalls Zoladex lot over cold-chain lapse; AstraZeneca's EMERALD-2 HCC trial completesOct 8Weekly roundup, 7 itemsAstraZenecaAZD7760Updated
AstraZeneca completes Phase 1 laroprovstat/ezetimibe bioavailability study in healthy adultsOct 2Weekly roundup, 6 itemsacalabrutinibanifrolumab-fnia
AstraZeneca-linked studies: OlympiaN, ZEAL and CHIO3 post results; two new studies registeredSep 25Weekly roundup, 7 itemsAstraZenecaAZD0120
AstraZeneca week: Imfinzi label update, ASSURE CLL results posted, four trials registeredSep 3Weekly roundup, 6 itemsacalabrutinibAstraZeneca
Summit's partner Akeso reports positive Phase III data for ivonescimab in bile duct cancerAug 26Clinical readoutivonescimabSummit Therapeutics
Incyte-backed trials: OSU tests pemigatinib cycling regimen; OHSU starts Opzelura pilot for PGAug 24Weekly roundup, 2 itemsIncyte Corporationpemigatinib
Olaparib Phase 2 results posted; three diabetes labels updated; new myeloma CAR-T trial recruitsAug 14Weekly roundup, 9 itemsAstraZenecaAZD0120
Theriva doses first patients in VIRAGE2 trial of VCN-01 in pancreatic cancerAug 11Quarterly updateTheriva Biologics, Inc.
AIM ImmunoTech reports Q2 2026 results, cites pancreatic cancer trial progress toward Phase 3Aug 10Quarterly updateAIM ImmunoTech Inc.
Arcus Biosciences advances casdatifan combinations, reports $775M cash at midyear 2026Aug 5Quarterly updateArcus Biosciences, Inc.AstraZeneca
Molecular Partners reports progress in Phase 2 TACTIC trial of MP0317 for cholangiocarcinomaJul 20Clinical readoutMolecular Partners AG